1. Home
  2. INLX vs OTLK Comparison

INLX vs OTLK Comparison

Compare INLX & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

HOLD

Current Price

$7.67

Market Cap

35.9M

Sector

Technology

ML Signal

HOLD

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

N/A

Current Price

$0.43

Market Cap

38.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INLX
OTLK
Founded
1996
2010
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.9M
38.7M
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
INLX
OTLK
Price
$7.67
$0.43
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$2.50
AVG Volume (30 Days)
888.0
1.1M
Earning Date
01-01-0001
06-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.91
EPS
N/A
N/A
Revenue
$11,336.00
$8,146,123.00
Revenue This Year
N/A
$1,726.70
Revenue Next Year
$15.82
$80.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.50
$0.38
52 Week High
$15.72
$3.39

Technical Indicators

Market Signals
Indicator
INLX
OTLK
Relative Strength Index (RSI) 42.50 43.02
Support Level $7.50 $0.39
Resistance Level $8.29 $0.46
Average True Range (ATR) 0.06 0.03
MACD -0.02 0.02
Stochastic Oscillator 25.00 65.86

Price Performance

Historical Comparison
INLX
OTLK

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: